

Medtronic releases 1-year hypertension ablation study | MassDevice.com On Call

Mass Device

Medical device giant Medtronic releases 1-year results from its Symplicity HTN-2 trial of renal ablation as treatment for drug-resistant hypertension.



MASSDEVICE ON CALL — Renal ablation continues to look good as a treatment for drug-resistant hypertension after 1 year of follow-up, according to newly released results of [Medtronic's](#) [1] (NYSE:[MDT](#) [2]) Symplicity HTN-2 trial.

Researchers directed "short bursts of radio waves" at the nerves surrounding the kidneys, successfully lowering blood pressure for at least 6 months and up to 1 year, according to the American Heart Assn.

"Studies will soon determine whether this procedure can cure mild hypertension, producing permanent drug-free normalization of blood pressure," Murray Esler, professor and senior director of the Baker IDI Heart & Diabetes Institute in Australia, said in [prepared remarks](#) [3]. "Based on the blood pressure declines achieved, reduction in heart attack and stroke rates of more than 40 percent is anticipated."

Source URL (retrieved on 01/27/2015 - 8:36pm):

<http://www.mdtmag.com/news/2012/12/medtronic-releases-1-year-hypertension-ablation-study-massdevicecom-call>

Links:

[1] <http://www.massdevice.com/company/medtronic>

[2] <http://www.google.com/finance?q=mdt>

[3] http://www.eurekalert.org/pub_releases/2012-12/aha-rwt121312.php